The only deals to get done this week were uplisted or completed on a best-efforts basis.
Although there were originally six IPOs on the calendar for this week, only Kura...read more
Kura Oncology, which is developing in-licensed protein inhibitors for solid tumors and blood cancers, raised $50 million by offering 6.25 million shares at $8 per share. The biotech, which is uplisting from the OTCQB (symbol: KURO), had last filed to raise $60...read more
In the last week of October, no companies filed for an IPO. October was a difficult month for IPOs: 16 companies went public, pricing an average of 22% below their midpoint....read more
Kura Oncology, which is developing protein inhibitor therapies for solid tumors and blood cancers, announced terms for its IPO on Wednesday. The La Jolla, CA-based company plans to raise $60 million, which would equate to an offering of 3.75 million shares...read more
US IPO Weekly Recap: All best-efforts and uplistings
The only deals to get done this week were uplisted or completed on a best-efforts basis. Although there were originally six IPOs on the calendar for this week, only Kura...read more
Cancer biotech Kura Oncology prices Nasdaq IPO at $8
Kura Oncology, which is developing in-licensed protein inhibitors for solid tumors and blood cancers, raised $50 million by offering 6.25 million shares at $8 per share. The biotech, which is uplisting from the OTCQB (symbol: KURO), had last filed to raise $60...read more
Week ahead: Two biotechs and a tech company
In the last week of October, no companies filed for an IPO. October was a difficult month for IPOs: 16 companies went public, pricing an average of 22% below their midpoint....read more
Cancer biotech Kura Oncology sets terms for $60 million Nasdaq IPO
Kura Oncology, which is developing protein inhibitor therapies for solid tumors and blood cancers, announced terms for its IPO on Wednesday. The La Jolla, CA-based company plans to raise $60 million, which would equate to an offering of 3.75 million shares...read more